AU2014216440B2 - Ultrapure tetrahydrocannabinol-11-oic acids - Google Patents

Ultrapure tetrahydrocannabinol-11-oic acids Download PDF

Info

Publication number
AU2014216440B2
AU2014216440B2 AU2014216440A AU2014216440A AU2014216440B2 AU 2014216440 B2 AU2014216440 B2 AU 2014216440B2 AU 2014216440 A AU2014216440 A AU 2014216440A AU 2014216440 A AU2014216440 A AU 2014216440A AU 2014216440 B2 AU2014216440 B2 AU 2014216440B2
Authority
AU
Australia
Prior art keywords
pct
acid
fibrosis
receptor
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014216440A
Other languages
English (en)
Other versions
AU2014216440A1 (en
Inventor
Dean A. Frey
David Goeddel
Karl E. Reineke
Mark Tepper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corbus Pharmaceuticals Inc
Original Assignee
Corbus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals Inc filed Critical Corbus Pharmaceuticals Inc
Publication of AU2014216440A1 publication Critical patent/AU2014216440A1/en
Application granted granted Critical
Publication of AU2014216440B2 publication Critical patent/AU2014216440B2/en
Priority to AU2018258159A priority Critical patent/AU2018258159B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014216440A 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids Ceased AU2014216440B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018258159A AU2018258159B2 (en) 2013-02-12 2018-11-05 Ultrapure tetrahydrocannabinol-11-oic acids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763630P 2013-02-12 2013-02-12
US61/763,630 2013-02-12
US201361837743P 2013-06-21 2013-06-21
US61/837,743 2013-06-21
PCT/US2014/016050 WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018258159A Division AU2018258159B2 (en) 2013-02-12 2018-11-05 Ultrapure tetrahydrocannabinol-11-oic acids

Publications (2)

Publication Number Publication Date
AU2014216440A1 AU2014216440A1 (en) 2015-08-20
AU2014216440B2 true AU2014216440B2 (en) 2018-08-09

Family

ID=51354671

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014216440A Ceased AU2014216440B2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids
AU2018258159A Ceased AU2018258159B2 (en) 2013-02-12 2018-11-05 Ultrapure tetrahydrocannabinol-11-oic acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018258159A Ceased AU2018258159B2 (en) 2013-02-12 2018-11-05 Ultrapure tetrahydrocannabinol-11-oic acids

Country Status (9)

Country Link
US (8) US20150141501A1 (enExample)
EP (2) EP2956133A4 (enExample)
JP (3) JP6689078B2 (enExample)
KR (2) KR20160002709A (enExample)
CN (2) CN105228613A (enExample)
AU (2) AU2014216440B2 (enExample)
BR (1) BR112015019180A8 (enExample)
CA (1) CA2900982C (enExample)
WO (1) WO2014127016A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6689078B2 (ja) 2013-02-12 2020-04-28 コーバス ファーマシューティカルズ インク． 超高純度なテトラヒドロカンナビノール−１１−酸
US20190133995A1 (en) * 2016-04-29 2019-05-09 Corbus Pharmaceuticals, Inc. Methods for the treatment of infection
EP3481371A1 (en) * 2016-07-11 2019-05-15 Intec Pharma Ltd. Oral gastroretentive formulations and uses thereof
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US20210284621A1 (en) * 2018-05-31 2021-09-16 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20200121614A1 (en) * 2018-10-18 2020-04-23 Bluegrass Farmacueticals, LLC Cannabinoid-infused transparent hydrogel skin patch
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
JP2022551863A (ja) 2019-10-11 2022-12-14 コーバス ファーマシューティカルズ インコーポレーテッド アジュレミン酸の組成物及びその使用
US20220023253A1 (en) * 2020-07-21 2022-01-27 Np Pharma Holdings, Llc Cannabinoid Compositions and Methods for Treating Joint Pain and Inflammation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8586767B2 (en) 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6974835B2 (en) 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7399872B2 (en) * 2001-03-07 2008-07-15 Webster G R Barrie Conversion of CBD to Δ8-THC and Δ9-THC
AU2003302578A1 (en) * 2002-12-04 2004-06-23 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
IL153277A0 (en) * 2002-12-04 2003-07-06 Pharmos Corp High enantiomeric purity dexanabinol for pharmaceutical compositions
US7413748B2 (en) 2002-12-13 2008-08-19 Purdue Pharma L.P. Transdermal buprenorphine to treat pain in sickle cell crisis
WO2004058251A1 (en) 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
AU2006240490A1 (en) 2005-04-21 2006-11-02 Paladin Labs (Barbados) Inc. Process for the preparation of ultrapure 4-methylprazole
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070037873A1 (en) 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
WO2007055806A1 (en) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
DK1903866T3 (en) 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
US20080054300A1 (en) * 2006-06-30 2008-03-06 Philip Gene Nikkel Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
US9192598B2 (en) 2008-06-25 2015-11-24 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
US20130338220A1 (en) 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
JP6689078B2 (ja) 2013-02-12 2020-04-28 コーバス ファーマシューティカルズ インク． 超高純度なテトラヒドロカンナビノール−１１−酸
US20150328198A1 (en) 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Also Published As

Publication number Publication date
JP6689078B2 (ja) 2020-04-28
CN105228613A (zh) 2016-01-06
JP2021185166A (ja) 2021-12-09
US9820964B2 (en) 2017-11-21
EP2956133A4 (en) 2016-12-21
US9801849B2 (en) 2017-10-31
US20150141501A1 (en) 2015-05-21
KR20190139327A (ko) 2019-12-17
US10369131B2 (en) 2019-08-06
US10154986B2 (en) 2018-12-18
AU2018258159B2 (en) 2020-01-02
WO2014127016A2 (en) 2014-08-21
AU2014216440A1 (en) 2015-08-20
CN110946854A (zh) 2020-04-03
AU2018258159A1 (en) 2018-11-22
KR20160002709A (ko) 2016-01-08
US20170071900A1 (en) 2017-03-16
US20180177757A1 (en) 2018-06-28
US20170071899A1 (en) 2017-03-16
CA2900982A1 (en) 2014-08-21
US20220117931A1 (en) 2022-04-21
JP2016510340A (ja) 2016-04-07
EP3851101A1 (en) 2021-07-21
BR112015019180A8 (pt) 2018-01-30
CA2900982C (en) 2021-06-01
JP2019031505A (ja) 2019-02-28
EP2956133A2 (en) 2015-12-23
US20190091200A1 (en) 2019-03-28
US11052066B2 (en) 2021-07-06
US20200093784A1 (en) 2020-03-26
US10085964B2 (en) 2018-10-02
WO2014127016A3 (en) 2015-11-26
US20170071898A1 (en) 2017-03-16
BR112015019180A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
US11052066B2 (en) Ultrapure tetrahydrocannabinol-11-oic acids
US20210198223A1 (en) Methods and compositions relating to ultrapure 5-(1,1-dimethylheptyl)-resorcinol
US20080227776A1 (en) Inhibitors of hemeprotein-catalyzed lipid peroxidation
KR101901741B1 (ko) 세스터터핀 화합물 및 이들 물질의 용도
WO2022256540A1 (en) Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
KR20150115809A (ko) 이소메텝텐 이성질체
HK40026965A (en) Ultrapure tetrahydrocannabinol-11-oic acids
US9133212B1 (en) Inhibitors of hemeprotein-catalyzed lipid peroxidation
CN117242076A (zh) 基于噻吩的化合物及其作为bckdk抑制剂的用途
US9545385B2 (en) Inhibitors of hemeprotein-catalyzed lipid peroxidation
CN110292637B (zh) 一种预防、治疗高血压的药物组合物
JP2025533120A (ja) イミダゾリジニルバニリン酸エーテル誘導体の線維化を伴う疾患の治療における使用
US20060154959A1 (en) Combination therapies of cicletanine and carvedilol
CN118019541A (zh) 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂
CN104873482A (zh) 一种抗慢性心力衰竭的药物组合物
OA18263A (en) A pharmaceutical composition comprising a beta blocker and an ACE inhibitor.

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ TEPPER, MARK; FREY, DEAN A.; GOEDDEL, DAVID AND REINEKE, KARL E.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ TEPPER, MARK; FREY, DEAN A.; GOEDDEL, DAVID AND REINEKE, KARL E.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired